News • Coronavirus research

Why the Omicron variant causes less severe disease

A new study by researchers from the University of Kent and the Goethe-University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defence mechanism against viruses, the so-called 'interferon response'. Moreover, cell culture findings indicate that eight important Covid-19 drugs and drug candidates remain effective against Omicron.

Moreover, cell culture findings indicate that eight important Covid-19 drugs and drug candidates remain effective against Omicron. 

The researchers published their findings in the journal Cell Reports.

Our data provide encouraging evidence that the available antiviral Covid-19 drugs are also effective against Omicron

Jindrich Cinatl

The SARS-CoV-2 Omicron variant causes less severe disease than Delta although it is better at escaping immune protection by vaccinations and previous infections. The reasons for this have so far remained elusive. A new study by a research team with scientists from the University of Kent and the Goethe-University Frankfurt has now shown that Omicron variant viruses are particularly sensitive to inhibition by the so-called interferon response, an unspecific immune response that is present in all body cells. This provides the first explanation of why Covid-19 patients infected with the Omicron variant are less likely to experience severe disease.

The cell culture study also showed that Omicron viruses remain sensitive to eight of the most important antiviral drugs and drug candidates for the treatment of Covid-19. This included 

  • EIDD-1931 (active metabolite of molnupiravir), 
  • ribavirin, 
  • remdesivir, 
  • favipravir, 
  • PF-07321332 (nirmatrelvir, active ingredient of paxlovid), 
  • nafamostat, 
  • camostat, and 
  • aprotinin.

Prof Martin Michaelis, School of Bioscience, University of Kent, said: “Our study provides for the first time an explanation, why Omicron infections are less likely to cause severe disease. Obviously, Omicron can in contrast to Delta not effectively inhibit the host cell interferon immune response.“ 

Prof. Jindrich Cinatl, Institute of Medical Virology at the Goethe-University, added: “Although cell culture experiments do not exactly recapitulate the more complex situation in a patient, our data provide encouraging evidence that the available antiviral Covid-19 drugs are also effective against Omicron.“ 


Source: Goethe-University Frankfurt

25.01.2022

Read all latest stories

Related articles

Photo

News • New insights into antibody response

How the immune system reacts to coronavirus variants

Researchers from Charité – Universitätsmedizin Berlin and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) present new findings on the immune response against SARS-CoV-2.

Photo

News • Sensitivity and response detection

How long do tests detect SARS-CoV-2 antibodies? New insights

How long can Covid-19 antigen tests reliably tell the antibody status? Researchers at the Paul-Ehrlich-Institut identified several factors that affect the detection duration.

Photo

News • Coronavirus research

Why Omicron may be more evasive, but less severe

The Omicron variant of SARS-CoV-2 may be significantly better at evading vaccine-induced antibodies – but preliminary evidence suggests it is less likely to cause severe illness in the lungs.

Related products

Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter – SARS-CoV-2 Assays

Immunoassays

Beckman Coulter – SARS-CoV-2 Assays

Beckman Coulter Diagnostics
Fujifilm Wako – μTASWako i30

Immunoassays

Fujifilm Wako – μTASWako i30

FUJIFILM Wako Chemicals Europe GmbH
Lifotronic  SARS-CoV-2 Antibody Detection Kit

Immunoassays

Lifotronic SARS-CoV-2 Antibody Detection Kit

Lifotronic Technology Co., Ltd
Subscribe to Newsletter